ASCO19: ribociclib combined with endocrine therapy increases survival in breast cancer patients

Written by Mike Gregg, Future Science Group

An international randomized phase III trial has discovered that adding ribociclib to endocrine therapy can significantly improve overall survival in premenopausal women with advanced HR-positive/HER2-negative breast cancer. The results showed that after 42 months of follow up the survival rate for women receiving combination therapy was 70% compared to 46% for women with endocrine therapy only. The study was recently presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (31 May – 4 June 2019, IL, USA). This research comes at an important time as advanced breast cancer is the leading cause of cancer death in women...

To view this content, please register now for access

It's completely free